Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Улучшение выживаемости при применении вемурафениба у пациентов с меланомой с мутацией BRAF V600E
2011-06-05
SCID: 54.1/yjba86er
Discuss with AI
BRAF V600E mutationmetastatic melanomaoverall survival and progression-free survivalphase 3 randomized clinical trial (BRIM-3)vemurafenib (PLX4032)
Figures from the paper
Abstract (AI)
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks). Coprimary end points were rates of overall and progression-free survival. Secondary end points included the response rate, response duration, and safety. A final analysis was planned after 196 deaths and an interim analysis after 98 deaths. RESULTS: At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. In the interim analysis for overall survival and final analysis for progression-free survival, vemurafenib was associated with a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P<0.001 for both comparisons). After review of the interim analysis by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended. Response rates were 48% for vemurafenib and 5% for dacarbazine. Common adverse events associated with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects. CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).
Key Findings
1
After interim analysis, crossover from dacarbazine to vemurafenib was recommended by the independent data and safety monitoring board.
2
Common adverse events with vemurafenib included arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% required dose modification for toxic effects.
3
In a phase 3 randomized trial of 675 previously untreated metastatic melanoma patients with BRAF V600E, vemurafenib improved 6-month overall survival to 84% versus 64% with dacarbazine.
4
Objective response rate was 48% with vemurafenib versus 5% with dacarbazine.
5
Vemurafenib reduced the risk of death by 63% compared with dacarbazine in interim overall survival analysis (P<0.001).
6
Vemurafenib reduced the risk of death or disease progression by 74% compared with dacarbazine in final progression-free survival analysis (P<0.001).
Research Object
Patients with previously untreated metastatic melanoma harboring the BRAF V600E mutation enrolled in a phase 3 trial comparing vemurafenib and dacarbazine
Research Subject
Effect of vemurafenib versus dacarbazine on overall survival and progression-free survival, response rate, response duration, and safety/toxicity in these patients
Publication Details
Publication Date
2011-06-05
Journal
Publisher
ISSN
Cited by
7862
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by7
The Cancer Genome Atlas Pan-Cancer analysis project2013
Pembrolizumab versus Ipilimumab in Advanced Melanoma2015
Cancer treatment and survivorship statistics, 20222022
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy2024
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma2014
European Standard Clinical Practice Recommendations for Cutaneous Melanoma in Children and Adolescents2026
Cancer immunotherapy: the beginning of the end of cancer?2016